BioCentury

4:27 PM GMT, Jun 12, 2018
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Emerging Company Profile

A Cancer Target Revolution

Revolution Medicines Inc. is developing inhibitors that target non-catalytic sites on proteins to block cell signaling pathways, such as Ras, that drive cancer cell proliferation.

The company’s platform combines synthetic and medicinal chemistry, biochemistry, and structural and computational biology components to design and build complex compounds from chemical fragments. CEO Mark Goldsmith told BioCentury that the use of modular methods allows systematic and repetitive coupling of fragments to build variants of a compound

Read the full 722 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.